Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 367

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 367
---
 have been personally involved in the development and/or regulatory approval
or clearance of multiple product candidates, comprising PMAs, 510(k)s, NDAs, BLAs as well as European CE marks. Members of the team have
also been involved in multiple investigational new drug applications (“INDs”) and investigational device exemption (“IDE”)
submissions to initiate the clinical development of new drugs, biologics and medical device products. Combined, the team has helped author
multiple patent applications. The executive team will be guided by a seasoned and highly accomplished board of directors with knowledge
and experience in the healthcare industry, as well as business operations, strategy, finance, and capital markets. Further, our product
development efforts are supported by world-renowned medical advisors who are physicians and scientists recognized for their knowledge
of specific disease states and existing treatment options, as well as their ability to quickly assess new technologies for clinical feasibility
and likelihood of adoption.

Research and Development

We invest in
research and development efforts that are designed to advance and expand our product pipeline. Our research and development goals are
to leverage our team’s collective knowledge and expertise to:

| ● | continuously discover and exploit scientific advances to discover new, cutting-edge approaches to solving 
 complex health problems in the longevity field;                                                           |

| ● | strategically deploy our financial resources to achieve the most direct and capital efficient path between 
 discovery and commercial approval; and                                                                     |

| ● | leverage the scientific advancements associated with our research and development programs to continuously 
 attract future partnerships with potential strategic partners.                                             |

| 195 |

We believe that our ability to develop new and
innovative product candidates is attributable to our dynamic product innovation process, the versatility and leveragability of our core
technology platforms and the talent of our scientific team to drive the research and development process. We will continue to recruit
and retain engineers and scientists with significant experience in the development of innovative longevity healthcare products and services.
Our current pipeline of product candidates that are in various stages of development are expected to provide additional strategic opportunities.
Our research and development facilities are based in Bothell, Washington.

Intellectual Property

Patents

Our success depends
in part on our ability to obtain, maintain, protect and enforce our proprietary technology and intellectual property rights, and, in particular,
our patent rights, as well as our ability to preserve the confidentiality of our trade secrets, and operate without infringing, misappropriating
or otherwise violating the valid and enforceable patents and other intellectual property rights of third parties